Thomas Equels News Today

OCALA, Fla., April 25, 2024 -- AIM ImmunoTech Inc.  , today announced the next CEO Corner segment has been published on the Company’s website. For the CEO Corner segment, Thomas Equels, Chief...

OCALA, Fla., April 11, 2024 -- AIM ImmunoTech Inc.  , today announced the next CEO Corner segment has been published on the Company’s website. For the CEO Corner segment, Thomas Equels, Chief...

(RTTNews) - Aim ImmunoTech Inc. (AIM) announced positive preliminary findings on Wednesday, showing that pairing Ampligen or rintatolimod with Key...

Operator: Hello. And welcome to the AIM ImmunoTech Fiscal Year 2023 Update Conference Call and Webcast. As a brief reminder, all participants are currently in a listen-only mode.

Operator: Hello, and welcome to the AIM ImmunoTech Quarterly Update Conference Call and Webcast. As a brief reminder, all participants are currently in a listen-only mode.

Operator: Hello, and welcome to the AIM ImmunoTech Quarterly Update Conference Call and Webcast. As a brief reminder, all participants are currently in a listen-only mode.

Operator: Hello, and welcome to the AIM ImmunoTech Inaugural Fiscal Year 2022 Update Conference Call and Webcast. As a brief reminder, all participants are currently in a listen-only mode.

The study will evaluate type-1 polarized dendritic cell (αDC1) vaccine in combination with tumor-selective chemokine modulation comprised of...

AIM ImmunoTech leadership offers new details on a potential Phase II trial of Ampligen in long Covid patients with chronic fatigue.

AIM ImmunoTech has reported positive initial pilot study data from its Phase III trial of an investigational drug, Ampligen, for long Covid.